Paratek Pharmaceuticals, Inc.
75 Park Plaza
About Paratek Pharmaceuticals, Inc.Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria.
Omadacycline is a new once-daily oral and IV, well-tolerated broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community acquired bacterial pneumonia, urinary tract infections and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.
Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily, oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Allergan initiated two identical Phase 3 registration studies in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris. Top line data are expected in the first half of 2017.
Board of Directors Michael F. Bigham Chairman of the Board and Chief Executive Officer
Evan Loh, MD Director and President, Chief Medical Officer
Thomas J. Dietz, Ph.D. Director
Timothy Franson, M.D., Director
Richard Lim Director
Kristine Peterson Director
Robert Radie Director
Jeffrey Stein, Ph.D. Director
Last Updated: 04-23-02
114 articles with Paratek Pharmaceuticals, Inc.
Allergan And Paratek Pharma Announce Positive Results From Two Phase III Trials Of Sarecycline For The Treatment Of Moderate To Severe Acne
Paratek Pharma Reports Full Year And Fourth Quarter 2016 Financial Results And Provides Clinical Update
Paratek Pharma Release: Company Announces Completion Of Enrollment In Omadacycline Phase III Community-Acquired Bacterial Pneumonia Study
Paratek Pharma Announces Promotion Of Evan Loh, M.D. To The Role Of President And Chief Operating Officer
Paratek Pharma Advances Timing Of Top-Line Data For Phase III Community Acquired Bacterial Pneumonia Study To The Second Quarter Of 2017
Paratek Pharma To Report Third Quarter 2016 Financial Results And Provide Update On Clinical Progress On November 2, 2016
Paratek Pharma, U.S. Department Of Defense Enter Research Agreement To Study Omadacycline Against Biodefense Pathogens